Associations between null mutations in GSTT1 and GSTM1, the GSTP1 Ile105Val polymorphism, and mortality in breast cancer survivors

SpringerPlus

Table 3 Associations between the Ile ¹⁰⁵ Val polymorphisms in GSTP1 , null mutations in GSTM1 and GSTT1 , and breast-cancer and all-cause mortality

Genotype	Events/N total	Unadjusted		Full Model^a		Events/N total	Radiotherapy+Chemotherapy only
		HR	95% CI	HR	95% CI		HR	95% CI
Breast cancer Mortality
*GSTM1*
Positive genotype	17/253	1.00	Ref.	1.00	Ref.	14/194	1.00	Ref.
Null genotype	28/280	1.48	0.81-2.71	0.93	0.49-1.79	21/213	0.88	0.41-1.86
P ^b			0.21		0.83			0.74
*GSTT1*
Positive genotype	11/109	1.00	Ref.	1.00	Ref.	8/86	1.00	Ref.
Null genotype	34/424	0.80	0.40-1.60	0.86	0.43-1.72	27/321	0.91	0.40-2.03
P ^b			0.54		0.68			0.80
*GSTP1*
Ile/Ile	16/233	1.00	Ref.	1.00	Ref.	14/176	1.00	Ref.
Ile/Val	26/250	1.53	0.82-2.86	1.66	0.87-3.16	19/185	1.37	0.67-2.84
Val/Val	3/60	0.75	0.22-2.58	0.63	0.17-2.27	2/46	0.42	0.10-2.12
P ^b			0.71		0.82			0.74
*GSTP1*
Ile/Ile	16/223	1.00	Ref.	1.00	Ref.	14/176	1.00	Ref.
Val/Val + Val/Ile	29/310	1.38	0.74-2.55	1.43	0.76-2.68	21/321	1.17	0.58-2.37
P ^b			0.30		0.27			0.67
All cause Mortality
*GSTM1*
Positive genotype	45/208	1.00	Ref.	1.00	Ref.	31/194	1.00	Ref.
Null genotype	54/226	1.07	0.71-1.58	0.88	0.57-1.34	38/213	0.77	0.45-1.30
P ^b			0.76		0.55			0.32
*GSTT1*
Positive genotype	17/109	1.00	Ref.	1.00	Ref.	12/86	1.00	Ref.
Null genotype	82/424	1.21	0.71-2.03	1.22	0.72-2.08	57/321	1.33	0.71-2.51
P ^b			0.48		0.47			0.38
*GSTP1*
Ile/Ile	30/223	1.00	Ref.	1.00	Ref.	24/176	1.00	Ref.
Ile/Val	59/250	1.89	1.21-2.95	1.98	1.25-3.12	39/185	1.72	1.01-2.93
Val/Val	10/60	1.41	0.68-2.89	1.24	0.59-2.58	6/46	0.60	0.20-1.75
P ^b			0.05		0.08			0.72
*GSTP1*
Ile/Ile	30/223	1.00	Ref.	1.00	Ref.	24/176	1.00	Ref.
Ile/Val + Val/Val	69/310	1.80	1.16-2.77	1.81	1.16-2.82	45/231	1.47	0.87-2.47
P ^b			0.008		0.008			0.15

^a Adjusted for race/ethnicity/study-site; BMI (categorical <18.5 kg/m²; ≥18.5 and <25 kg/m²; ≥25 and <40 kg/m²; ≥40 kg/m²); SEER summary tumor stage (local vs. regional) and treatment received at diagnosis (surgery; surgery+radiotherapy; chemotherapy).
^b Wald test for trend.
Boldface type indicates a statistically significant result.